Background Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of
anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives …

Background: Coagulopathy and thromboembolic events are common in Covid‐19 patients
and are poor prognostic factors. Controversy exists regarding the potential of …

Abstract Background Coronavirus disease 2019 (COVID-19) is associated with a
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease
severity during hospitalization but the reported survival benefits from anticoagulation (AC) …

Background COVID-19 infection is associated with D-dimer elevations, high rates of
thrombus formation, and poor clinical outcomes. We sought to determine if empiric …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …